N-terminal proBNP and mortality in hospitalised patients with heart failure and preserved vs. reduced systolic function: data from the prospective Copenhagen Hospital Heart Failure Study (CHHF).
about
Limitations of the New York Heart Association functional classification system and self-reported walking distances in chronic heart failureValue of N-terminal pro brain natriuretic peptide in the elderly: data from the prospective Copenhagen Hospital Heart Failure study (CHHF).Interatrial shunt devices for heart failure with normal ejection fraction: a technology update.Natriuretic peptides (BNP and NT-proBNP): measurement and relevance in heart failureInfluence of previous heart failure hospitalization on cardiovascular events in patients with reduced and preserved ejection fraction.The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis.Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction.Correlation of N-terminal fragment of B-type natriuretic peptide levels with clinical, laboratory, and echocardiographic abnormalities in children with sickle cell disease.N-terminal proBNP: a novel biomarker for the diagnosis, risk stratification and management of congestive heart failure.The Importance of Amino-terminal pro-Brain Natriuretic Peptide Testing in Clinical Cardiology.ProANP plasma measurement predicts all-cause mortality in acutely hospitalised patients: a cohort study.Society of Chest Pain Centers recommendations for the evaluation and management of the observation stay acute heart failure patient-parts 1-6.The prognostic significance of heart failure with preserved left ventricular ejection fraction: a literature-based meta-analysis.A new tissue Doppler index to predict cardiac death in patients with heart failure.Natriuretic peptides in heart failure: where we are, where we are going.Hyponatraemia at hospital admission is a predictor of overall mortality.Effects of intermittent and long-term glucose-insulin-potassium infusion in patients with systolic heart failure.Accuracy of a heart failure diagnosis in administrative registers.Pentraxin-3 level at admission is a strong predictor of short-term mortality in a community-based hospital setting.The prognostic value of a new tissue Doppler parameter in patients with heart failure.Natriuretic peptides for heart failure. Fashionable? Useful? Necessary?Multicentre evaluation of a new point-of-care test for the determination of NT-proBNP in whole blood.Amino-terminal pro-brain natriuretic peptide: a biomarker for diagnosis, prognosis and management of heart failure.NT-proBNP levels, echocardiographic findings, and outcomes in breathless patients: results from the ProBNP Investigation of Dyspnoea in the Emergency Department (PRIDE) echocardiographic substudy.Association between diffuse myocardial fibrosis and diastolic dysfunction in sickle cell anemia.N-terminal pro-B-type natriuretic peptide predicts cardiovascular complications in pregnant women with congenital heart disease.Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trialPrognostic utility of NT-proBNP greater than 70,000 pg/mL in patients with end stage renal disease
P2860
Q22306537-9728AB97-9F32-4F5F-8F29-01A91847E8F5Q30908639-6F63EA1F-1446-4DCD-B521-D5809D13AE07Q33812836-82F423BB-85E9-4006-ADFF-D068E8B908E1Q33902623-2D54BCF9-B018-4C14-950A-8BF84D1E673AQ33916711-C4466DB8-965F-4FF9-A7AB-D086A036578BQ33984662-C4F4D1F9-EB4B-4206-9693-F23737BEBDB3Q34528187-DB3020A5-EFBA-4399-BCB3-87CFEAAF9493Q35742699-72A56CCD-57C2-4A87-9583-00A42440EA74Q36124913-815B1CE9-4EA2-4270-827E-50AD2F569CADQ37277937-5E9A259E-C9A3-4196-B1D0-DF737810A6F9Q37352819-DB245876-EB45-46BF-AD21-FA0BF34BD495Q37461040-6E479B33-F5B4-475C-91E9-BD1D3AA77A68Q37572119-F0D6DF3D-4993-449A-AB7B-A33A39214DDEQ37703933-00DBE8AB-DACE-45EC-88C5-3A81C078373DQ37790310-D7ED2D74-4877-41E6-91F7-FEB531D1B750Q40232884-D9855931-441A-48D9-9222-092E94CAEFB1Q41674725-21B92EE5-2F37-41A1-8934-4DB77ECF71C2Q43737933-8A441F94-0FC5-43F9-B647-B661866FAE22Q45110914-4FC37E62-4DEE-498B-8AFD-C105F77B5511Q46219929-AB4FBFB7-CE79-40D8-A290-0E5F2F771791Q48030240-F8B7D9B7-7BC7-4230-9E37-9B3C21953547Q48399619-F9CE65D1-5218-4532-BD75-BEC21FCE6500Q48409814-DBA1C046-69F5-42BF-B5F2-038EE0CF282AQ48631855-9B98D985-3E7E-4536-A2D5-B326BB75693FQ51000056-33DF13C4-6630-4BE9-B959-E3F9D3065136Q54445625-6FFFA2E7-E922-4503-8895-A851D11F2269Q57396177-2DD7A34C-85A6-4336-932D-A4ACE32782BCQ58570628-A1BE0BC2-C573-4523-978E-A4CD1CA329AB
P2860
N-terminal proBNP and mortality in hospitalised patients with heart failure and preserved vs. reduced systolic function: data from the prospective Copenhagen Hospital Heart Failure Study (CHHF).
description
2004 nî lūn-bûn
@nan
2004 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի մարտին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
N-terminal proBNP and mortalit ...... al Heart Failure Study (CHHF).
@ast
N-terminal proBNP and mortalit ...... al Heart Failure Study (CHHF).
@en
type
label
N-terminal proBNP and mortalit ...... al Heart Failure Study (CHHF).
@ast
N-terminal proBNP and mortalit ...... al Heart Failure Study (CHHF).
@en
prefLabel
N-terminal proBNP and mortalit ...... al Heart Failure Study (CHHF).
@ast
N-terminal proBNP and mortalit ...... al Heart Failure Study (CHHF).
@en
P2093
P2860
P921
P1476
N-terminal proBNP and mortalit ...... tal Heart Failure Study (CHHF)
@en
P2093
Aldershvile J
Boesgaard S
Hassager C
Nielsen OW
P2860
P304
P356
10.1016/J.EJHEART.2004.01.002
P577
2004-03-01T00:00:00Z